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Abstract  
BACKGROUND: Hepatitis C virus is one of the most common etiologic agents of chronic liver 
diseases, including liver cirrhosis and hepatocellular carcinoma in which there is continuous 
inflammation and regeneration of hepatocytes.Cytokeratin-18 (CK18) has been suggested to play 
an important role in tumorigenesis of epithelial cancers. 
AIM: Estimation of CK18 serum levels in patients with chronic viral hepatitis C (CHCV) and 
hepatocellular carcinoma (HCC) and find the relationship between their levels, the severity of the 
disease and the development of HCC.  
METHODS: We measured serum levels of CK18 in 60 Egyptian patients (30 with CHCV & 30 with 
HCC) and 30 healthy controls. 
RESULTS: Patients with HCC had highly significant increased CK18 levels compared with CHCV 
patients, healthy controls. Cytokeratin-18 among the three classes of Child-Pugh classification 
show highly significant gradual increase from child A to C. Furthermore, In HCC there were positive 
correlations between CK18 and with RBCs, ESR, and AFP. 
CONCLUSION: CK18 is a sensitive indicator of the severity of liver disease. Patients with CHCV 
infection can be followed up by measurement of its serum level which can predict the development 
of HCC. The combination of AFP and CK18 increased the sensitivity of detection for HCC.                                                      
 
 
 
 
 
Introduction 
 
Hepatitis C is a significant public health 
problem in Egypt where the prevalence is estimated to 
be 14, 7% in general population. Hepatitis C virus 
prevalence is even higher among clinical populations 
and groups at risk of exposure to infection [1].  
Hepatitis C virus is considered the most 
common etiology of chronic liver disease (CLD) in 
Egypt. The disease severity ranges from mild illness 
to cirrhosis and hepatocellular carcinoma (HCC) [2] 
which are the most common causes of death in 
patients with (CLD). Chronic liver injury of virtually any 
etiology triggers inflammatory and wound-healing 
responses that in the long run promote the 
development of hepatic fibrosis and HCC [3]. 
Hepatocellular carcinoma was listed as the 
third most lethal cancer type [4]. The symptoms and 
signs of HCC are vague and rarely appear until the 
cancer has spread throughout the liver, if liver cancer 
is diagnosed in its early stages, it can be treated by 
surgically removing part of the liver, by liver 
transplantation, or by a radiofrequency ablation [5]. 
Prognosis for patients with HCC depends on 
tumor stage, with curative therapies only available for 
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patients detected at an early stage. Patients detected 
at an early stage can achieve 5-year survival rates of 
70% with transplant or resection, whereas those with 
advanced HCC are only eligible for palliative 
treatments and have a median survival of less than 
one year [6].  
The diagnosis of HCC without pathologic 
confirmation can be achieved by assessing the serum 
alpha-fetoprotein (AFP) level combined with imaging 
techniques, including ultrasonography, magnetic 
resonance imaging, and computerized tomography 
[7] , but effective test strategies should be considered 
to improve the early diagnostic rate of HCC including 
the combined detection of several serum markers that 
can complete each other in order to improve the early 
diagnostic rate [8].  
Cytokeratins are proteins of keratin-containing 
intermediate filaments found in the intracytoplasmic 
cytoskeleton of epithelial tissue. The cytokeratins can 
be divided into low versus high molecular weight 
based on their molecular weight. Expression of these 
cytokeratins is frequently organ or tissue specific. In 
the cytoplasm, the keratin filaments conform a 
complex network which extends from the surface of 
the nucleus to the cell membrane [9]. 
Keratin 18 is a type I cytokeratin. It is, 
together with its filament partner keratin 8, perhaps 
the most commonly found products of 
the intermediate filament gene family. They are 
expressed in single layer epithelial tissues of the 
body. Mutations in this gene have been linked 
to cryptogenic cirrhosis. Two transcript variants 
encoding the same protein have been found for this 
gene [10].  
Cytokeratin 18 is also called tissue 
polypeptide specific antigen representing about 5% of 
total protein in the liver, exocrine pancreas, intestine 
and other epithelial tissues [11]. CK18 has been 
suggested to play an important role in tumorigenesis 
of epithelial cancers [12]. Also Christoph etal., 2009 
[13] found that soluble CK18 fragments (M30, M65) 
are released from human cancer cells during cell 
death.  
In the study of Bantel and coworkers, raised 
concentrations of CK18 fragments were evident in 
HCV patients with liver fibrosis even in the absence of 
elevated aminotransferase [14].  
The aim of this study was to estimate of 
CK18 serum levels in patients with chronic viral 
hepatitis C (CHCV) and hepatocellular carcinoma 
(HCC) and to find the relationship between their 
levels, the severity of the disease and the 
development of HCC. 
 
 
 
Patients and Methods 
 
 This study was conducted on 60 adult 
patients:  30 patients with CHCV infection and 30 
patients with HCC who presented to Tropical, Internal 
Medicine Department of Al-Zahraa University Hospital 
from March to November 2014. The study also 
included 30 healthy subjects who were clinically, 
laboratory and ultrasonographically free served as a 
control group.  
 
Inclusion criteria 
Adult patients (>18 years), both sexes (males 
or females) and patients with CHCV infection (either 
compensated or decompensated) or HCC were 
included. 
 
Exclusion criteria   
Patients with history or evidence of other 
malignancies, patients suffering from any other organ 
failure and other causes of cirrhosis e.g. alcohol were 
excluded.   
                                                                                                                              
Subject groups and investigations 
Group 1 (G1): Included 30 patients with 
chronic HCV infection either compensated (18) or 
decompensated (12) they were (14 males, 16 
females), their ages ranged from 35-60 years old with 
mean of (47.9 ± 6.67). 
Group 2(G2): Included 30 patients with HCC 
on top of chronic HCV infection (22 males, 8 females), 
their ages ranged from 45-62 years old with mean of 
(55.4 ± 5.85).                                                                                                                     
Group 3: Included 30 healthy subjects with no 
clinical, laboratory or ultrasonographic evidence of 
liver disease served as a control group (13 males, 17 
females), their ages ranged from 25-47 years old with 
mean of (32.2 ± 7.01).                                                                                                                                                                                                                                
Patients groups were sub-classified according 
to the severity of liver disease using modified Child's-
Pugh classification system to assess CK18 serum 
levels in relation to the progression of liver disease. 
All patients and controls were subjected to the 
following:                                              
1. Full history and clinical examination. 
2. Abdominal ultrasonography.                                                                                     
  3. Abdomino-pelvic triphasic CT scan for 
suspected cases of HCC. Liver biopsy and 
histopathological examination was done when needed 
for patients with hepatic focal lesions not fulfilling 
imaging or AFP diagnostic criteria for HCC.                                 
El-Zefzafy et al. Serum Cytokeratin-18 in Prediction of Hepatocellular Carcinoma 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
OA Maced J Med Sci. 2015 Mar 15; 3(1):117-123.                                                                                                                                                                         119 
 
   4. Laboratory investigations: Three ml of 
fasting (6-8 hours) of fasting venous blood samples 
was taken from each subject participating in the study 
and divided into three portions as follows:  
 First portion was collected into Na citrate -
containing tube, and used for estimation of 
prothrombin time (PT) immediately on 
automated blood coagulation analyzer 
Sysmex CA1500 (Siemens AG, Erlangen, 
Germany) and for ESR estimation by 
Westergren´s method.    
 The second portion was collected into EDTA 
containing tube for CBC estimation using 
Coulter Counter T890 (Coulter LH 750 
analyzer, Berlin, Germany). 
 The third portion was put in a plan tube, left to 
clot then centrifuged at 1600 rpm for 20 
minutes and serum was separated and used 
for estimation of:  
 Liver  and  kidney  function  tests  were  done  
on  Hitachi  911  auto-analyzer (Roche-
Hitachi, Japan).  
 Hepatitis makers (HBsAg, HCV Ab) based on 
Enzyme Linked Immunosorbent Assay 
(ELISA) technique, by ADVANCED HBsAG 
ELISA Test Kit Catalogue number; 
ITP21201Rev.40202, and for HCVAb in 
serum: Detected by ELISA third generation, 
using kit from ORTHO. Catalogue number; 
631300942.  
- Serum Alpha fetoprotein (AFP) was detected by 
COBAS e411 chemiluminescence auto analyzer using 
Roche reagents (Roche Diagnostics GmbH, D-68289 
Mannheim, Germany) (Qin et al., 2011) [15]. 
- Serum CK18 assay was performed using ELISA 
kit supplied from DRG International Inc. (841 
Mountain Avenue, Springfield, New Jersey 07081, 
USA, Catalogue number EIA 2354. Briefly, standards, 
controls and samples react during incubation 
simultaneously with a solid phase monoclonal catcher 
antibody and the HRP-conjugated detector antibody 
(M3). After washing, the TMB substrate is added and 
after an incubation time the reaction is stopped and 
the absorbance at 450 nm is measured. The level of 
CK18 was calculated from standard curve 
corresponding to the measured optical density. The 
results were expressed as U/L. Minimum detectable 
limit of CK18 ranged from 30 - 1200 U/L. [16].   
 
Statistical analysis 
Data was analyzed using Microsoft Excel 
2007. Parametric data was expressed as mean ± SD 
and non-parametric data was expressed as number 
and percentage. Student’s t test was done to compare 
between groups. Pearson Correlation Coefficient was 
done to correlate between different parameters 
among groups. Analysis of Variance (ANOVA) test 
was used to estimate the difference between the 
means of more than two groups. P value of > 0.05 
considered non significant, P value of ≤ 0.05 
considered significant, P value of < 0.001 was 
considered highly significant.  
 
 
Results 
 
The results and data were collected and 
analyzed in tables 1-5 &Figures 1-4: As regard the 
result of personal data of the studied groups: there 
was highly significant difference in age among the 
studied groups with a significant male predominance 
in GII in comparison to GI  (Table1). 
Table 1: Age and sex distribution of the studied groups. 
 Groups 
G 1 
(n=30) 
G 2 
(n=30) 
Control 
(n=30) 
P-value 
 
Age(years) 
Mean  
± SD 
47.9 
 ± 6.67 
55.4 
± 5.85 
32.2 
± 7.01 
0.001        
Sex 
Males 
No. 14 22 13 
0.03    
    
% 46% 73% 40% 
Females 
No. 16 8 17 
% 54% 27% 60% 
G1: CHCV; G2: HCC.  
 
There were significant decrease in 
hemoglobin (Hb) level, in G II in comparison to GI, 
control group at P value (≤ 0.05). highly significant 
decrease in platelets count (PLT) count, increase in 
ESR in G II in comparison to GI &control group while 
no significant difference in WBCs, RBCs was detected 
among the studied groups (Table 2). 
Table 2: Comparison of complete blood picture among the 
studied groups (Mean ± SD). 
 Groups P 
 Group I Group II Control GI/Control GII/Control G I/G II 
WBCs 
(Thousands/cmm) 
6.50 ± 2.98 6.6 ± 3.22 5.9 ±1.36 0.57 0.50 0.87 
RBCs 
(Millions/cmm) 
4.08± 0.46 4.5 ±0.4 4.23±0.72 0.35 0.76 0.43 
Hemoglobin 
(gm/dl) 
12± 2.20 10.8±1.73 12.8 ±1.94 0.39 0.010 0.062 
Platelets 
(Thousands/cmm) 
200± 93.7 116±50 255 ±39.8 0.086 <0.001 0.001 
ESR 
(mm/H) 
23.3±18.2 85.2 ±37.6 9.9±1.5 0.006 <0.001 <0.001 
P>0.05: non significant; (P <0.05): significant; (p<0.001): highly significant. 
 
Our results revealed highly significant 
increase in ALT, decrease in prothrombin time (PT) & 
serum albumin in GII in comparison to control group at 
P value (<0.001) and significant increase in AST& 
Total(T)Bilirubin & alkalin phosphatase (ALKPH) in 
GI,GII in comparison to control group, with significant 
decrease in (PT) & serum albumin& T.Bilirubin in GII 
in comparison to GI (Table 3). 
Concerning the result of serum AFP there 
was significant increase in its levels in GII in 
comparison to GI, control group with sensitivity and 
specificity 45% and 96.6%, respectively (3 patients in  
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Table 3: Comparison of Biochemical characteristics among the 
studied groups (Mean ±SD). 
 
G I 
(n=30) 
G II 
(n=30) 
Control 
(n=30) 
P-value 
GI/Control 
P-value 
GII/Control 
P-value 
G I/G II 
ALT 
IU/L 
Mean 48.5 53.6 22.2 
0.048   0.001 0.63 
±SD 39.6 25.6 5.57 
AST 
IU/L 
Mean 54.5 57.7 25.1 
0.017 0.01 0.78 
±SD 36.0 33.3 8.13 
PC% Mean 65.6 53.3 96.4 <0.001 <0.001 0.029   
±SD 14.4 19.6 6.33 
Albumin 
gm/dl 
Mean 3.24 2.56 4.31 
<0.001 0.001 0.004 
±SD 0.803 0.564 0.303 
T.Bilirubin
g/dl 
Mean 1.43 3.05 0.62 
<0.001 0.004 0.01 
±SD 0.604 2.43 0.2 
Alkph 
IU/L 
Mean 131 173 72.4 
0.025   0.006 0.16 ±SD 76.6 106 18.4 
±SD 102 95.6 26.0 
 
**HS: highly significant at p<0.001; S: ≤ 0.05 significant; NS: non significant at p>0.05. 
 
G2 with hepatic focal lesions, AFP was below 
diagnostic level for HCC so liver biopsy and histo-
pathological examination was done) while serum 
CK18 was highly significantly increased in GII in com-
parison to GI and control group with sensitivity and 
specificity of 95% and 96.7% (Fig. 1, 2), (Table 4). 
 
Figure 1: Comparison of serum cytokeratin-18 among the studied 
groups. 
 
 
Figure 2: Serum α-fetoprotein (AFP) among the studied groups. 
 
CK18 among the three classes of Child-Pugh 
classification show highly significant gradual increase 
from child A to C in G1 and G2 patients (Fig. 3). 
 
Figure 3: Serum cytokeratin-18 among the three classes of Child-
Pugh classification. 
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Figure 4: The receiver operating characteristic curves cytokeratin-
18, serum (AFP). 
 
ROC Curve Analysis: Area under ROC curve 
at 95% CI for CK18 by extended trapezoidal rule = 
0.998333 with Optimum cut-off point selected = 534.5 
while for AFP it was = 0.966667 with Optimum cut-off 
point selected= 134 for HCC diagnosis (Fig. 4). 
In GI there was significant negative 
correlation   between   serum   CK18   &   hemoglobin,  
Table 4: Sensitivity, specificity, positive predictive value, 
negative predictive value, positive, negative (likelihood ratio) of 
cytokeratin-18, α-fetoprotein. 
 
 
Sensitivity Specificity PPV NPV +LR -LR 
Optimum cut-off 
point selected 
CK18 
(U/L) 
95% 96.7% 94.7 96.7 28.4 0.054 543 
AFP  
(ng/mL) 
45% 96.6% 90 72.5 13.5 0.57 134 
 
PPV (positive predictive value), NPV (negative predictive value), +LR (positive likelihood  
ratio), -LR ( negative likelihood). 
platelets, serum albumin, positive correlation with 
RBCs, ESR, serum AFP while in GII there was only 
positive correlation with serum AFP (Table 5). 
Table 5: Correlations between serum cytokeratin-18 serum 
levels and laboratory data in the studied patients (n=40). 
 
GI  GII  
r P-value r P-value 
Age 0.319 0.175 0.006 0.977 
Hemoglobin -0.456 0.043 0.107 0.653 
RBCs 0.09 0.705 0.126 0.652 
WBcs -0.303 0.194 0.012 0.959 
Platelets -0.679 <0.001 0.354 0.125 
ESR 0.550 0.011 0.255 0.276 
ALT -0.048 0.840 -0.061 0.796 
AST 0.160 0.499 -0.104 0.662 
T.B 0.184 0.435 0.269 0.262 
albumin -0.555 0.011 -0.149 0.530 
PC -0.411 0.071 -0.376 0.102 
Alkph 0.057 0.811 0.049 0.835 
AFP 0.840 <0.001 0.996 <0.001 
 
 
Discussion                                                                                                          
 
Hepatitis C virus (HCV) is a global health 
problem with an estimated 170-200 million peoples 
(approximately 3% of world population) are chronically 
infected worldwide and new infections are predicted to 
be on rise in coming years. HCV infection remains 
categorized as a major risk factor for chronic hepatitis, 
liver cirrhosis and hepatocellular carcinoma worldwide 
[17].The discovery of an effective, reliable tool for 
early diagnosis of HCC to increase the number of 
patients who are suitable for curative treatment will 
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play a pivotal role in improving HCC patients’ 
prognosis [7].  
  Liver cell damage in CHCV infection is 
mediated by the induction of apoptosis, the key 
morphological alterations of apoptosis are mediated 
by a family of intracellular cysteine proteases, called 
caspases (mainly caspase-3) [18], which cleave a 
number of different substrates inside the cell—
including (CK-18), the major intermediate filament 
protein in the liver—resulting in the characteristic 
morphologic changes of apoptosis which has a role in 
liver damage caused by CHCV infection [19]. Studies 
have confirmed that CK-18 secretion occurs in parallel 
with DNA synthesis, protein synthesis, and cell 
division [20].   
In the present study, the mean age of G 2 
was higher than G 1, this result is similar to studies by 
Mittal, and El-Serag  [21]   as they found that in high 
incidence areas, HCC is reported to develop in the 
fifth decade of life.  In our study, a male predominance 
was noted in HCC group, this was close to what was 
mentioned by Avunduk [22] who reported that HCC 
was more common in men with percentage of 80%. 
As regard the blood picture, our study 
demonstrated highly significant decrease in platelets 
count in G 2 in comparison to GI and the control 
group. Lu etal., [23] reported that, thrombocytopenia 
was a valid surrogate of cirrhosis and a valid marker 
for the identification of individuals at high-risk for HCC, 
especially in areas that had a high prevalence of HCV. 
No significant difference in total leukocytic 
count was observed in G 2 in comparison to G 1 or 
the control group, on the other hand Friedman [24] 
who categorized persistent leukocytosis as one of the 
paraneoplastic syndromes associated with HCC. 
Our results revealed significant increase of 
serum ALT in GI in comparison to control group, 
significant increase of serum AST in GI, GII in 
comparison to control group. Bantel et al., [14] 
observed that more than 50% of patients with CHCV 
with normal aminotransferases exhibited already 
elevated serum caspase activity which revealed 
higher stages of fibrosis. Arturo etal., [25] reported 
that serum CK18 levels correlated with liver markers, 
particularly serum AST. 
Moreover, in our study serum CK18, revealed 
a highly significant increase of its level in patients with 
CHCV this is in agreement with Arturo et al.,[25]. The 
mechanism causing increased CK18 concentrations in 
chronic hepatitis patients is unknown, but may be 
related to the marked sensitivities of this protein for 
nonneoplastic tissue in rapid regeneration, cell lysis, 
sinusoidal flow, and metabolism of glycoprotein 
markers [26]. On comparing the results of serum CK-
18 in GI, GII, control group with that of 
aminotransferases we found that it may be a more 
sensitive marker for the detection of liver injury. 
We demonstrated a highly significant 
difference in serum CK18 levels between patients with 
HCC and healthy controls. Our results agree with 
Dom-Gene et al., [27] however, they found the 
difference between the HCC and chronic hepatitis 
groups was not significant at (P = 0.18) but we found it 
highly significant at P <0.001. They added that a high 
serum Ck18 concentration would not be expected to 
distinguish HCC from hepatic metastases because 
this antigen is derived none selectively from malignant 
cells and elevated concentrations are found in the 
serum of patients with a wide variety of malignant 
diseases, some of which metastasize to the liver. 
In our study the sensitivity and specificity of 
serum Ck-18 were 95% and 96.7%, respectively, with 
a cutoff value of 534.5 U/L for HCC diagnosis. While 
Dom-Gene et al., [27]   found The sensitivity and 
specificity of serum Ck-18  were 73.1% and 71.2%, 
respectively, at a cut-off value of 164 (U/L) for a HCC 
diagnosis in Chinese patients.    
Kao et al., [31] reported elevated serum Ck-
18 levels in hepatitis B carriers with a low specificity 
for discriminating between hepatitis B carriers and 
HCC . In our study, we found progressive highly 
significant gradual increase in serum CK18 parallel to 
the severity of liver disease as assessed by Child's-
Pugh classification, these findings agree with the 
results of Collazos etal., [26].  
Abdel Haleem et al., [32]  found the serum 
level and the hepatic expression of CK-18 are related 
to disease activity and are directly correlated with 
METAVIR scoring So, monitoring the serum CK-18 
levels can limit the need for liver biopsy for detection 
of their tissue levels. 
In addition, serum CK18 levels correlated with 
Knodell's score in patients with chronic hepatitis [25]. 
In contrast to our result no statistical correlation was 
found with liver markers except negative correlation 
with serum albumin in GI.   
In GI& GII there was significant positive 
correlation between serum CK18 and serum AFP 
which has been regarded as the most useful serum 
protein thus far for patients at risk for HCC. However, 
its sensitivity for detecting HCC ranges between 25%-
60% and its specificity is also low because serum AFP 
can also be detected in patients with cirrhosis (11%-
47%) and chronic hepatitis (15%-58%) [4]. In addition 
to AFP, more than 20 serum proteins have clinical 
significance in early diagnosis of HCC [28], among 
which several proteins are proved to have advantages 
over AFP. There have been recent advances in 
technology that have enabled early identification of 
the process of hepatocarcinogenesis [29]. 
Concerning our result of (AFP) there was 
significant increase in its serum levels in HCC group 
in comparison to CHCV group, control group with no 
significant difference in CHCV group in comparison to 
control group. 
We found serum concentrations of AFP 
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elevated in 30% of CHCV patients with a mean value 
19.4ng/mL. These results go parallel with the results 
of El-Serag et al., [4]   while the percentage jumps to 
100% for Ck-18 with a mean value 348U/L with a 
highly significant difference in CHCV group in 
comparison to control group.  This is in agreement 
with Gallo et al., [30].  
Therefore, serum Ck-18 is more valuable than 
serum AFP for the diagnosis of HCC in contrast to 
Dom-Gene et al., [27] who said that Ck-18 is less 
valuable than AFP for the diagnosis of HCC because 
AFP is produced by the tumor, and only tumors 
originating in the gastrointestinal tract or yolk sac 
tumors complicated by hepatic metastases are likely 
to be mistaken clinically for HCC. 
In conclusion, serum CK18 levels are 
significantly high in patients with CHCV; patients with 
HCC have the highest serum levels that might 
correlate its pathophysiology. Serum CK-18 levels 
may be useful for monitoring disease activity in 
CHCV, liver cirrhosis and HCC patients. The 
combination of AFP and CK18 increased the 
sensitivity of detection for HCC. 
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